AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...
Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...
AstraZeneca, Advagene Biopharma, Genrix (Shanghai) Biopharmaceuticals, and others are evaluating new severe asthma drugs to improve the announced positive headline results from the phase III ...
GlobalData on MSN1d
Are dry powder inhalers the key to sustainable respiratory care?Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...
Healthcare Asia on MSN6d
Here's why severe asthma market is growingOver 40 companies are working on more than 50 therapies for severe asthma. The severe asthma market is growing due to a ...
Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.
Respiratory medicine is one of AstraZeneca's core therapy areas ... eosinophil monoclonal antibody benralizumab, a treatment for severe asthma, before the end of 2016. Johnson & Johnson has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback